HRP20191233T1 - Antitijela lakog lanca modificirana histidinom i genetski modificirane nehumane životinje za dobivanje istih - Google Patents
Antitijela lakog lanca modificirana histidinom i genetski modificirane nehumane životinje za dobivanje istih Download PDFInfo
- Publication number
- HRP20191233T1 HRP20191233T1 HRP20191233TT HRP20191233T HRP20191233T1 HR P20191233 T1 HRP20191233 T1 HR P20191233T1 HR P20191233T T HRP20191233T T HR P20191233TT HR P20191233 T HRP20191233 T HR P20191233T HR P20191233 T1 HRP20191233 T1 HR P20191233T1
- Authority
- HR
- Croatia
- Prior art keywords
- human
- light chain
- rodent
- gene
- sequence
- Prior art date
Links
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 title claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 235000014304 histidine Nutrition 0.000 claims 21
- 241000283984 Rodentia Species 0.000 claims 20
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 17
- 238000006467 substitution reaction Methods 0.000 claims 17
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 16
- 150000002411 histidines Chemical class 0.000 claims 15
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 11
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108020004705 Codon Proteins 0.000 claims 6
- 210000004602 germ cell Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 230000008707 rearrangement Effects 0.000 claims 4
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (12)
1. Genetski modificirani glodavac koji u svojoj zametnoj liniji sadrži lokus imunoglobulinskog lakog lanca koji sadrži dva nepreuređena humana segmenta gena Vκ i jedan ili više nepreuređenih humanih segmenata gena Jκ operativno povezanih sa sekvencom konstantne regije imunoglobulinskog lakog lanca,
naznačeno time, što su nepreuređeni humani segmenti gena Vκ humani segmenti gena Vκ1-39 i Vκ3-20, od kojih svaki sadrži jednu ili više supstitucija nehistidinskog CDR3 kodona histidinskim kodonom,
naznačeno time, što su humani segmenti gena Vκ i Jκ sposobni za preuređenje, a humani segmenti gena Vκ i Jκ šifriraju varijabilnu domenu humanog lakog lanca koja sadrži jedan ili više histidina, pri čemu su jedan ili više histidina dobiveni iz jedne ili više supstitucija,
naznačeno time, što je (i) supstitucija jednog ili više histidna humanog segmenta gena Vκ1-39 te je supstitucija dizajnirana za izražavanje jednog ili više histidina na poziciji odabranoj iz skupine koja se sastoji od 105, 106, 108 i 111 humanog segmenta gena Vκ1-39 (prema numeriranju IMGT) i njihove kombinacije; i/ili (ii) supstitucija jednog ili više histidina humanog segmenta gena Vκ3-20 te je supstitucija dizajnirana za izražavanje jednog ili više histidina na poziciji odabranoj iz skupine koja se sastoji od 105, 106, 107 i 109 humanog segmenta gena Vκ3-20 (prema numeriranju IMGT) i njihove kombinacije, i
naznačeno time, što glodavac dodatno u svojoj zametnoj liniji sadrži lokus imunoglobulinskog teškog lanca koji sadrži nepreuređenu sekvencu varijabilne regije imunoglobulinskog teškog lanca koja sadrži humane segmente gena VH, DH i JH operativno povezane sa sekvencom konstantne regije imunoglobulinskog teškog lanca.
2. Glodavac prema patentnom zahtjevu 1, naznačen time, što:
(i) glodavac ne sadrži endogeni segment gena varijabilne regije lakog lanca κ koji je sposoban za preuređenje kako bi formirao imunoglobulinski laki lanac;
(ii) sekvenca konstantne regije imunoglobulinskog lakog lanca je nehumana sekvenca konstantne regije imunoglobulinskog lakog lanca, opcionalno naznačena time, što je nehumana sekvenca konstantne regije imunoglobulinskog lakog lanca mišja ili štakorska sekvenca ili što je nehumana sekvenca konstantne regije imunoglobulinskog lakog lanca endogena sekvenca konstantne regije imunoglobulinskog lakog lanca;
(iii) sekvenca konstantne regije imunoglobulinskog teškog lanca je nehumana sekvenca konstantne regije imunoglobulinskog teškog lanca, kao što je mišja ili štakorska sekvenca;
(iii) dva nepreuređena humana segmenta gena Vκ i jedan ili više nepreuređenih humanih segmenata gena Jκ su prisutni na endogenom lokusu imunoglobulinskog lakog lanca; ili
(iv) konstantna regija imunoglobulinskog lakog lanca je Cκ regija.
3. Glodavac prema patentnom zahtjevu 1, naznačen time, što je nehumana sekvenca konstantne regije imunoglobulinskog teškog lanca endogena nehumana sekvenca konstantne regije imunoglobulinskog teškog lanca.
4. Glodavac prema patentnom zahtjevu 1, naznačen time, što je glodavac štakor ili miš.
5. Glodavac prema patentnom zahtjevu 1, naznačen time, što glodavac sadrži populaciju B stanica kao odgovor na interesni antigen koja je obogaćen za antitijela koja izražavaju smanjenje disocijativnog poluživota (t1/2) pri kiseloj pH vrijednosti u usporedbi s neutralnom pH vrijednošću od najmanje 2 puta, najmanje 3 puta, najmanje 4 puta, najmanje 5 puta, najmanje 10 puta, najmanje 15 puta, najmanje 20 puta, najmanje 25 puta ili najmanje 30 puta.
6. Glodavac prema patentnom zahtjevu 1, naznačen time, što glodavac sadrži pet humanih segmenata Jκ, a tih pet humanih segmenata Jκ su segmenti Jκ1, Jκ2, Jκ3, Jκ4 i Jκ5.
7. Glodavac prema patentnom zahtjevu 1, naznačen time, što lokus imunoglobulinskog lakog lanca ne sadrži više od humanih segmenata gena Vκ1-39 i Vκ3-20 i jedan ili više nepreuređenih humanih segmenata gena Jκ koji su operativno povezani sa sekvencom konstantne regije imunoglobulinskog lakog lanca.
8. Glodavac prema patentnom zahtjevu 7, naznačen time, što svaki nepreuređeni humani segment gena Vκ1-39 i Vκ3-20 sadrži supstituciju tri ili četiri nehistidinska CDR3 kodona histidinskim kodonima, opcionalno naznačen time, što:
(i) supstitucija humanog gena Vk1-39 je dizajnirana za izražavanje histidina na pozicijama 106, 108 i 111 humanog segmenta gena Vκ1-39;
(ii) supstitucija humanog gena Vκ1-39 je dizajnirana za izražavanje histidina na položajima 105, 106, 108 i 111 humanog segmenta gena Vκ1-39;
(iii) supstitucija humanog segmenta gena Vκ3-20 je dizajnirana za izražavanje histidina na položajima 105, 106, i 109 humanog segmenta gena Vκ3-20;
(iv) supstitucija humanog segmenta gena Vκ3-20 je dizajnirana za izražavanje histidina na položajima 105, 106, 107 i 109 humanog segmenta gena Vκ3-20.
9. Glodavac prema patentnom zahtjevu 1, naznačen time, što glodavac izražava populaciju antitijela specifičnih za antigen kao odgovor na antigen, naznačen time, što sva antitijela u populaciji sadrže:
varijabilne domene imunoglobulinskog lakog lanca dobivene iz preuređivanja nepreuređenih humanih segmenata gena Vκ1-39 i Vκ3-20 i jednog ili više nepreuređenih humanih segmenata Jκ, i
imunoglobulinske teške lance koji sadrže humane varijabilne domene teškog lanca dobivene iz niza humanih teških segmenata V, D i J.
10. Metoda za dobivanje glodavca koji sadrži genetski modificirani lokus imunoglobulinskog lakog lanca u svojoj zametnoj liniji, pri čemu se metoda sastoji od:
modificiranja genoma zametne linije glodavca radi brisanja ili postizanja nefunkcionalnosti endogenih segmenata gena Vκ i Jκ imunoglobulinskog lakog lanca u lokusu imunoglobulinskog lakog lanca, i
umetanja u genom zametne linije nehumane životinje varijabilne regije imunoglobulinskog lakog lanca koja sadrži dva nepreuređena humana segmenta gena V Vκ i najmanje jedan nepreuređeni humani segment gena Jκ, tako da je sekvenca varijabilne regije imunoglobulinskog lakog lanca operativno povezana sa sekvencom konstantne regije imunoglobulina,
naznačeno time, što su dva nepreuređena humana segmenta gena Vκ humani segmenti gena Vκ1-39 i Vκ3-20, od kojih svaki sadrži jednu ili više supstitucija nehistidinskog CDR3 kodona histidinskim kodonom,
naznačeno time, što su nepreuređeni humani segmenti gena Vκ i Jκ sposobni za sposobni za preuređenje, a nepreuređeni humani segmenti gena Vκ i Jκ šifriraju varijabilnu domenu humanog lakog lanca koja sadrži jedan ili više histidina koji su dobiveni iz jedne ili više supstitucija,
naznačeno time, što je (i) supstitucija jednog ili više histidna humanog segmenta gena Vκ1-39 te je supstitucija dizajnirana za izražavanje jednog ili više histidina na poziciji odabranoj iz skupine koja se sastoji od 105, 106, 108 i 111 humanog segmenta gena Vκ1-39 (prema numeriranju IMGT) i njihove kombinacije; i/ili (ii) supstitucija jednog ili više histidina humanog segmenta gena Vκ3-20 te je supstitucija dizajnirana za izražavanje jednog ili više histidina na poziciji odabranoj iz skupine koja se sastoji od 105, 106, 107 i 109 humanog segmenta gena Vκ3-20 (prema numeriranju IMGT) i njhove kombinacije, i
naznačeno time, što glodavac dodatno u svojoj zametnoj liniji sadrži lokus imunoglobulinskog teškog lanca koji sadrži nepreuređenu sekvencu varijabilne regije imunoglobulinskog teškog lanca koja sadrži humane segmente gena VH, DH i JH operativno povezane sa sekvencom konstantne regije imunoglobulinskog teškog lanca.
11. Metoda prema patentnom zahtjevu 10, naznačena time, što:
(i) varijabilna regija imunoglobulinskog lakog lanca se nalazi na endogenom nehumanom lokusu imunoglobulinskog lakog lanca; ili
(ii) glodavac je miš ili štakor.
12. Metoda za dobivanje antitijela koje izražava vezivanje za interesni antigen ovisno o pH vrijednosti koja se sastoji od:
imunizacije glodavca prema patentnom zahtjevu 1 interesnim antigenom te odabira antitijela koje se vezuje za interesni antigen sa željenim afinitetom pri neutralnoj pH vrijednosti uz istovremeno ispoljavanje smanjenog vezivanja za interesni antigen pri kiseloj pH vrijednosti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/030,424 US20140013456A1 (en) | 2012-03-16 | 2013-09-18 | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| EP14781761.3A EP3046412B1 (en) | 2013-09-18 | 2014-09-18 | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| PCT/US2014/056285 WO2015042250A1 (en) | 2013-09-18 | 2014-09-18 | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191233T1 true HRP20191233T1 (hr) | 2019-10-18 |
Family
ID=51663490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191233TT HRP20191233T1 (hr) | 2013-09-18 | 2019-07-10 | Antitijela lakog lanca modificirana histidinom i genetski modificirane nehumane životinje za dobivanje istih |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP3046412B1 (hr) |
| JP (3) | JP6621750B2 (hr) |
| KR (2) | KR102150414B1 (hr) |
| CN (2) | CN105722387B (hr) |
| AU (2) | AU2014323527B2 (hr) |
| BR (1) | BR112016005912A2 (hr) |
| CA (1) | CA2922892C (hr) |
| CY (1) | CY1121798T1 (hr) |
| DK (1) | DK3046412T3 (hr) |
| ES (2) | ES2738679T3 (hr) |
| HK (1) | HK1225913A1 (hr) |
| HR (1) | HRP20191233T1 (hr) |
| HU (1) | HUE044747T2 (hr) |
| IL (2) | IL244226B (hr) |
| LT (1) | LT3046412T (hr) |
| MX (1) | MX362904B (hr) |
| MY (1) | MY191512A (hr) |
| PL (1) | PL3046412T3 (hr) |
| PT (1) | PT3046412T (hr) |
| RS (1) | RS59003B1 (hr) |
| RU (2) | RU2019121863A (hr) |
| SG (2) | SG11201601272YA (hr) |
| SI (1) | SI3046412T1 (hr) |
| TR (1) | TR201909967T4 (hr) |
| WO (1) | WO2015042250A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| CN113416257A (zh) | 2011-11-30 | 2021-09-21 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
| BR112015001955A2 (pt) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | variante de região fc específica de fcgamariib |
| US10766960B2 (en) | 2012-12-27 | 2020-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| MX2015014017A (es) | 2013-04-02 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Variante de la region fc. |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| CN111556895B (zh) | 2017-11-14 | 2024-09-13 | 中外制药株式会社 | 抗-c1s抗体及使用方法 |
| WO2020132557A1 (en) * | 2018-12-21 | 2020-06-25 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
| JP2023508290A (ja) * | 2019-12-18 | 2023-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | 共通のリーダー配列を有するｂｃｒトランスジェニックマウス |
| WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CN114568343B (zh) * | 2022-03-11 | 2023-04-07 | 成都合拓创展生物科技有限公司 | 制备眼病模型的头具及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PT1802193E (pt) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Método para gerar um murganho homozigótico para uma modificação genética |
| EP2505058A1 (en) * | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| BRPI0712224B8 (pt) | 2006-06-02 | 2021-05-25 | Regeneron Pharma | anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas |
| TR201808046T4 (tr) * | 2008-04-11 | 2018-06-21 | Chugai Pharmaceutical Co Ltd | İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü. |
| AU2009313389A1 (en) * | 2008-11-06 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| DE112010002931T5 (de) | 2009-07-16 | 2012-08-30 | Wageningen Universiteit | Regulierung von Zinkmangel und Zinktoleranz bei Pflanzen |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| US20130096281A1 (en) * | 2010-01-21 | 2013-04-18 | Oxyrane Uk Limited | Methods and compositions for displaying a polypeptide on a yeast cell surface |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| KR101829691B1 (ko) | 2010-02-08 | 2018-02-19 | 리제너론 파마슈티칼스 인코포레이티드 | 일반적인 경쇄 마우스 |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| CA2792740A1 (en) * | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | Antibodies with ph dependent antigen binding |
| SI3034608T1 (sl) * | 2010-06-22 | 2019-06-28 | Regeneron Pharmaceuticals, Inc. | Miši, ki izražajo hibridno lahko verigo imunoglobulina s humano variabilno regijo |
| US8367586B2 (en) * | 2010-11-19 | 2013-02-05 | Morphosys Ag | Collection and methods for its use |
| EP3778889A1 (en) * | 2011-09-30 | 2021-02-17 | Chugai Seiyaku Kabushiki Kaisha | Ion concentration-dependent binding molecule library |
| US20140013456A1 (en) * | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| RU2017114166A (ru) * | 2013-02-20 | 2019-01-29 | Регенерон Фармасьютикалс, Инк. | Не являющиеся человеком животные с модифицированными последовательностями тяжелых цепей иммуноглобулинов |
-
2014
- 2014-09-18 EP EP14781761.3A patent/EP3046412B1/en active Active
- 2014-09-18 CA CA2922892A patent/CA2922892C/en active Active
- 2014-09-18 HU HUE14781761 patent/HUE044747T2/hu unknown
- 2014-09-18 TR TR2019/09967T patent/TR201909967T4/tr unknown
- 2014-09-18 SG SG11201601272YA patent/SG11201601272YA/en unknown
- 2014-09-18 BR BR112016005912A patent/BR112016005912A2/pt not_active IP Right Cessation
- 2014-09-18 WO PCT/US2014/056285 patent/WO2015042250A1/en active Application Filing
- 2014-09-18 MY MYPI2016700599A patent/MY191512A/en unknown
- 2014-09-18 SI SI201431271T patent/SI3046412T1/sl unknown
- 2014-09-18 PT PT14781761T patent/PT3046412T/pt unknown
- 2014-09-18 DK DK14781761.3T patent/DK3046412T3/da active
- 2014-09-18 AU AU2014323527A patent/AU2014323527B2/en active Active
- 2014-09-18 RS RS20190873A patent/RS59003B1/sr unknown
- 2014-09-18 RU RU2019121863A patent/RU2019121863A/ru unknown
- 2014-09-18 ES ES14781761T patent/ES2738679T3/es active Active
- 2014-09-18 MX MX2016003638A patent/MX362904B/es active IP Right Grant
- 2014-09-18 CN CN201480061443.XA patent/CN105722387B/zh active Active
- 2014-09-18 KR KR1020167009721A patent/KR102150414B1/ko active IP Right Grant
- 2014-09-18 SG SG10201810825YA patent/SG10201810825YA/en unknown
- 2014-09-18 ES ES19159475T patent/ES2962489T3/es active Active
- 2014-09-18 KR KR1020207024599A patent/KR20200103882A/ko not_active Application Discontinuation
- 2014-09-18 PL PL14781761T patent/PL3046412T3/pl unknown
- 2014-09-18 EP EP19159475.3A patent/EP3549437B1/en active Active
- 2014-09-18 JP JP2016543984A patent/JP6621750B2/ja active Active
- 2014-09-18 LT LTEP14781761.3T patent/LT3046412T/lt unknown
- 2014-09-18 RU RU2016114306A patent/RU2694728C2/ru active
- 2014-09-18 CN CN201911266988.5A patent/CN111019953A/zh active Pending
-
2016
- 2016-02-22 IL IL244226A patent/IL244226B/en active IP Right Grant
- 2016-12-16 HK HK16114363A patent/HK1225913A1/zh unknown
-
2019
- 2019-01-16 JP JP2019004905A patent/JP2019068850A/ja not_active Withdrawn
- 2019-01-21 IL IL264358A patent/IL264358A/en unknown
- 2019-07-10 HR HRP20191233TT patent/HRP20191233T1/hr unknown
- 2019-07-10 CY CY20191100728T patent/CY1121798T1/el unknown
-
2020
- 2020-03-03 JP JP2020035905A patent/JP2020078350A/ja not_active Withdrawn
-
2021
- 2021-01-15 AU AU2021200228A patent/AU2021200228A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191233T1 (hr) | Antitijela lakog lanca modificirana histidinom i genetski modificirane nehumane životinje za dobivanje istih | |
| HRP20191333T1 (hr) | Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost | |
| HRP20190706T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
| HRP20220888T1 (hr) | Ne-humane životinje koje imaju konstruirani lokus imunoglobulinskog lamba lakog lanca | |
| HRP20190807T1 (hr) | Miševi koji izražavaju imunoglobulinski hibridni laki lanac s humanom varijabilnom regijom | |
| HRP20191680T1 (hr) | Neljudske životinje koje izražavaju antitijela sa zajedničkim lakim lancem | |
| HRP20151188T4 (hr) | Miš sa zajedničkim lakim lancem | |
| SI2825036T1 (en) | Light chain antibodies with built-in histidine and genetically modified rodents for their formation | |
| JP2015510767A5 (hr) | ||
| HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
| HRP20211126T1 (hr) | Humanizirane nehumane životinje s ograničenim lokusima imunoglobulinskog teškog lanca | |
| JP2015502177A5 (hr) | ||
| HRP20192218T1 (hr) | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene | |
| HRP20192255T1 (hr) | Humanizirani miševi s univerzalnim lakim lancem | |
| JP2015505477A5 (hr) | ||
| JP2014529998A5 (hr) | ||
| HRP20171357T1 (hr) | Ograničeni teški lanac imunoglobulina u miševa | |
| JP2014516518A5 (hr) | ||
| HRP20231356T1 (hr) | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže | |
| JP2020530760A5 (hr) | ||
| JP2015525071A5 (hr) | ||
| HRP20230497T1 (hr) | Glodavci koji izražavaju egzogenu terminalnu dezoksinukleotidil transferazu | |
| RU2016141123A (ru) | Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики | |
| RU2015137173A (ru) | Разработка иммуногена на основе в-клеточной линии дифференцировки с использованием гуманизированных животных | |
| RU2022109215A (ru) | Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl |